PharmaLedger Association Launches Digital Trust Ecosystem in Healthcare
BASEL, Switzerland, March 13, 2023 (GLOBE NEWSWIRE) -- The PharmaLedger Association™ (PLA), a not-for-profit based in Switzerland, announces the endorsement of its 3-year strategic plan to implement and promote a Digital Trust Ecosystem in healthcare (DTE-H) at its Annual General Meeting held in Lucerne, Switzerland on 1 March 2023. The member organizations also confirmed the appointment of eight Directors to its board, delivering on PLA’s core value of “Ecosystem Leadership.”
Representing the diversity of healthcare, PLA’s founding members comprise of large and small pharmaceutical companies, research organizations, patient representative organizations, non-profit organizations, technology, and healthcare service providers. PLA has confirmed its mandate as a pre-competition umbrella organization delivering common and interoperable digital solutions in the areas of Product Trust, Decentralized Clinical Trials, and Supply Chain Traceability.
- Products & Project: In Q1 2023, PLA will release the first qualified product, electronic Product Information for implementation by its members.
In Q2 2023, the Association will continue with the development of new products in its innovation xLab, including of a product digital twin, decentralized identities, and verifiable credentials to facilitate visibility, security, traceability, and trust in all areas of healthcare.
- Governance & Compliance: PLA will leverage its capability to develop, qualify, launch, and maintain products in healthcare’s highly regulated environment by ensuring continuous adherence to antitrust, intellectual property, data privacy, and Computerized System Assurance guidelines.
- Ecosystem Engagement & Growth: The association will continue to onboard new members and engage with authorities, trade associations and standards development organizations, ensuring growth and financial viability.
- Platform Technology & Security: PLA will focus on easing adoption of new solutions with its members and users while maintaining the cybersecurity benefits of its architecture.
The formation of PLA and the endorsement of its mission by diverse members of healthcare is a major milestone. This paves the way for delivery of widely trusted blockchain-based platforms with new open-source healthcare solutions to create value for patients and ecosystem stakeholders. PLA is grateful to its 20 founding members and invites all healthcare related organizations to learn more and engage towards the realization of a trusted Healthcare 4.0.
“Blockchain is a team sport. PLA has started with a diverse and strong team of members with a common vision and who believe in real change. With PLA we have the right vehicle, resources, and roadmap to take patients to a better place in healthcare,”Daniel Fritz, Executive Director, PharmaLedger Association.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
PLA is the result of the successful completion of the PharmaLedger research project, a €22 million, 30-member consortium with 12 large pharma companies and 18 public partners, funded under the European Union (EU) and European Federation of Pharmaceutical Industries and Associations (EFPIA)’s Innovative Health Initiative.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/0682572a-b8ac-4b5b-885b-8af008287cff
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Fortuna files Form 40-F, Annual Report30.3.2023 23:15:00 CEST | Press release
VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Fortuna Silver Mines Inc. (NYSE: FSM) (TSX: FVI) reports that the Company has filed today its fiscal 2022 annual report on Form 40-F with the U.S. Securities and Exchange Commission (“SEC”). The Form 40-F, which includes the Company’s fiscal 2022 annual audited financial statements, management’s discussion and analysis, and annual information form, is available on the Company’s website and on the SEC´s website. Printed copies of the annual financial statements are available free of charge to Fortuna shareholders upon written request. About Fortuna Silver Mines Inc. Fortuna Silver Mines Inc. is a Canadian precious metals mining company with four operating mines in Argentina, Burkina Faso, Mexico and Peru, and a fifth mine under construction in Côte d'Ivoire. Sustainability is integral to all our operations and relationships. We produce gold and silver and generate shared value over the long-term for our stakeholders through
Samlede antal stemmerettigheder og aktiekapital i Pharma Equity Group A/S ("Selskabet")30.3.2023 23:13:48 CEST | pressemeddelelse
Pharma Equity Group A/S Selskabsmeddelelse Årets meddelelse nr.: 24 Dato: 30. marts 2023 Samlede antal stemmerettigheder og aktiekapital i Pharma Equity Group A/S ("Selskabet") I henhold til Lov om kapitalmarkeder (lovbekendtgørelse nr. 41 af 13. januar 2023) § 32 offentliggør Selskabet hermed det samlede antal stemmerettigheder og den samlede aktiekapital i Selskabet. Efter kapitalforhøjelse registreret den 24. marts 2023 vedrørende udstedelse af vederlagsaktier til aktionærerne i Reponex Pharmaceuticals A/S og nye aktier med fortegningsret for Selskabets eksisterende aktionærer i en fortegningsretsemission, hvor Selskabet i alt udstedte 978.584.263 stk. nye aktier à nominelt DKK 1,00 pr. aktie, udgør Selskabets samlede nominelle aktiekapital DKK 1.022.963.883 svarende til 1.022.963.883 antal aktier og 1.022.963.883 stemmer pr. 31. marts 2023 Yderligere information Alle henvendelser vedrørende ovenstående bedes venligst rettet til direktør Peter Ole Jensen på e-mailadressen: peter.ole
Multitude Group Annual Report for 2022 published30.3.2023 22:45:00 CEST | Press release
Multitude Group Annual Report for 2022 published Helsinki, 30 March 2023 – Multitude SE (ISIN: FI4000106299, WKN: A1W9NS) (“Multitude” or the “Group”) is pleased to announce that the Group's Annual Report, Corporate Governance Statement and Remuneration Report for the year ended 31 December 2022 have been published today on the company’s website. The Annual Report consists of annual review and financial review, including Board of Directors‘ report, consolidated financial statements and parent company’s financial statements. The annual review includes the ESG Report 2022 which comprises the non-financial statement. It outlines the Group’s ESG Goals and KPIs focused on people, processes, and the environment, with commencement of reporting on the Group’s carbon emissions. The ESG report 2022 further highlights the Group’s commitment to customer well-being through responsible lending practices and the introduction of a Responsible Lending Index and a commitment to progress on employee well
Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion30.3.2023 22:45:00 CEST | Press release
Company announcement – No. 11 / 2023 Zealand Pharma announces completion of a directed issue and private placement of 6,578,948 million new ordinary shares raising gross proceeds of DKK 1.5 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA, EXCEPT AS PERMITTED BY APPLICABLE LAW. THIS ANNOUNCEMENT IS NOT AN OFFER OF SECURITIES FOR SALE IN THE UNITED STATES AND THE SECURITIES REFERRED TO HEREIN MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES ABSENT REGISTRATION EXCEPT PURSUANT TO AN EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT; ANY PUBLIC OFFERING OF SUCH SECURITIES TO BE MADE IN THE UNITED STATES WILL BE MADE BY MEANS OF A PROSPECTUS THAT MAY BE OBTAINED FROM THE ISSUER, WHICH WOULD CONTAIN DETAILED INFORMATION ABOUT THE COMPANY AND MANAGEMENT, AS WELL AS FINANCIAL STATEMENTS. As announced on 30 March 2023, Zealand Pharma commenced
Multitude SE: Notice to Convene Multitude SE's Annual General Meeting of Shareholders30.3.2023 22:45:00 CEST | Press release
NOTICE TO CONVENE MULTITUDE SE’S ANNUAL GENERAL MEETING OF SHAREHOLDERS Notice is given to the shareholders of Multitude SE (Company) that the Annual General Meeting of the Company is to be held on 27 April 2023 at 10:00 a.m. (EEST / Finnish time) at the offices of Castrén & Snellman Attorneys Ltd, Eteläesplanadi 14, Helsinki, Finland. The reception of persons who have registered for the meeting and the distribution of voting tickets will start at 9:30 a.m. (EEST / Finnish time). Shareholders may also exercise their voting rights by voting in advance. Instructions concerning advance voting are provided in Section 3.4 of this notice. It will not be possible to participate in the meeting or follow the meeting via an online stream or otherwise in real time by the use of telecommunication connections or technical means. The meeting will be held in the English language. 1 MATTERS ON THE AGENDA OF THE GENERAL MEETING OF SHAREHOLDERS At the General Meeting of Shareholders, the following matte